// App-Quantinova.ai

POS03 : Clinical outcomes following off-label use vs. established indications of bioresorbable scaffolds in a real-world population

Researchers

Presenter

  • Miyazaki T

Principal Investigators

  • Latib A

  • Ruparelia N

  • Kawamoto H

  • Figini F

  • Colombo A

Medical Centers

  • San Raffaele Scientific Institute, Milan, Italy

Locations

  • United Kingdom

  • Italy

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Myocardial infarction

  • Diabetes

  • Venous thrombosis

Biomarkers

  • Acetyl-CoA carboxylase

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved